Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Rijcken CJ"'
Autor:
Biancacci I; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., De Santis D; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany.; University of Urbino, Department of Biomolecular Sciences, Piazza Rinascimento 6, 61029, Urbino, Italy., Rama E; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Benderski K; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Momoh J; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Pohlberger R; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Moeckel D; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Kaps L; University Medical Center of the Johannes Gutenberg-University Mainz, Department of Internal Medicine 1, Langenbeckstrasse 1, 55131, Mainz, Germany.; University Medical Center of the Johannes Gutenberg-University Mainz, Institute of Translational Immunology and Research Center for Immunotherapy/FZI), Obere Zahlbacher Str. 63, 55131, Mainz, Germany., Rijcken CJ; Cristal Therapeutics, Oxfordlaan 55, 6229 EV, Maastricht, The Netherlands., Prakash J; University of Twente, Engineered Therapeutics Section, Department of Advanced Organ Bioengineering and Therapeutics, Technical Medical Centre, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands., Thewissen M; Cristal Therapeutics, Oxfordlaan 55, 6229 EV, Maastricht, The Netherlands., Kiessling F; RWTH Aachen University, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany.; Fraunhofer Institute for Digital Medicine MEVIS, Max-Von-Laue-Strasse 2, 28359, Bremen, Germany., Shi Y; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Peña Q; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Sofias AM; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Consolino L; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany., Lammers T; RWTH Aachen University, Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Forckenbeckstrasse 55, 52074, Aachen, Germany.
Publikováno v:
Advanced therapeutics [Adv Ther (Weinh)] 2023 Jul 19; Vol. 6 (11). Date of Electronic Publication: 2023 Jul 19 (Print Publication: 2023).
Autor:
Atrafi F; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Eerden RAG; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., van Hylckama Vlieg MAM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Lolkema MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Moelker A; Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, the Netherlands., Rijcken CJ; Cristal Therapeutics, Maastricht, the Netherlands., Hanssen R; Cristal Therapeutics, Maastricht, the Netherlands., Sparreboom A; Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, Ohio., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. s.koolen@erasmusmc.nl.; Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jul 15; Vol. 26 (14), pp. 3537-3545. Date of Electronic Publication: 2020 Apr 22.
Autor:
Hu Q; Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands., Rijcken CJ; Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands., van Gaal E; Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands., Brundel P; Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands., Kostkova H; Institute of Macromolecular Chemistry, the Czech Academy of Sciences, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic., Etrych T; Institute of Macromolecular Chemistry, the Czech Academy of Sciences, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic., Weber B; Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany., Barz M; Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany., Kiessling F; Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen 52074, Germany., Prakash J; Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands., Storm G; Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584CG, The Netherlands., Hennink WE; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584CG, The Netherlands., Lammers T; Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen 52074, Germany; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584CG, The Netherlands. Electronic address: tlammers@ukaachen.de.
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2016 Dec 28; Vol. 244 (Pt B), pp. 314-325. Date of Electronic Publication: 2016 Jul 09.
High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration.
Autor:
Hu Q; Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, 7500AE, The Netherlands; Cristal Therapeutics, Oxfordlaan 55, Maastricht, 6229EV, The Netherlands., Prakash J; Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, 7500AE, The Netherlands., Rijcken CJ; Cristal Therapeutics, Oxfordlaan 55, Maastricht, 6229EV, The Netherlands., Hennink WE; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584CG, The Netherlands., Storm G; Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, 7500AE, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, 3584CG, The Netherlands. Electronic address: g.storm@uu.nl.
Publikováno v:
International journal of pharmaceutics [Int J Pharm] 2016 Nov 30; Vol. 514 (1), pp. 112-120.
Autor:
Hu Q; Department of Biomaterials Science and Technology, section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Cristal Therapeutics, Maastricht, The Netherlands., van Gaal EV; Cristal Therapeutics, Maastricht, The Netherlands., Brundel P; Cristal Therapeutics, Maastricht, The Netherlands., Ippel H; Department of Biochemistry and CARIM, University of Maastricht, Maastricht, The Netherlands., Hackeng T; Department of Biochemistry and CARIM, University of Maastricht, Maastricht, The Netherlands., Rijcken CJ; Cristal Therapeutics, Maastricht, The Netherlands., Storm G; Department of Biomaterials Science and Technology, section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Hennink WE; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Prakash J; Department of Biomaterials Science and Technology, section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. Electronic address: j.prakash@utwente.nl.
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2015 May 10; Vol. 205, pp. 98-108. Date of Electronic Publication: 2015 Jan 10.
Autor:
Talelli M; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.; Department of Immunology and Oncology and NanoBiomedicine Initiative, Centro Nacional de Biotecnología (CNB)/CSIC, Darwin 3, Cantoblanco, 28049 Madrid, Spain., Barz M; Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany., Rijcken CJ; Cristal Therapeutics, Oxfordlaan 55, 6229 EV Maastricht, the Netherlands., Kiessling F; Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany., Hennink WE; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Lammers T; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.; Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen, Germany.; Department of Controlled Drug Delivery, University of Twente and MIRA Institute for Biomedical Technology and Technical Medicine, Enschede, The Netherlands.
Publikováno v:
Nano today [Nano Today] 2015 Feb 01; Vol. 10 (1), pp. 93-117.
Autor:
Hu Q; Department of Biomaterials Science and Technology, Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500AE, The Netherlands; Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands., Rijcken CJ; Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands., Bansal R; Department of Biomaterials Science and Technology, Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500AE, The Netherlands., Hennink WE; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584CG, The Netherlands., Storm G; Department of Biomaterials Science and Technology, Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500AE, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584CG, The Netherlands., Prakash J; Department of Biomaterials Science and Technology, Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500AE, The Netherlands; Cancer Centre Karolinska, Karolinska Institutet, Stockholm SE-171 76, Sweden. Electronic address: j.prakash@utwente.nl.
Publikováno v:
Biomaterials [Biomaterials] 2015; Vol. 53, pp. 370-8. Date of Electronic Publication: 2015 Mar 18.
Autor:
Talelli M; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Oliveira S, Rijcken CJ, Pieters EH, Etrych T, Ulbrich K, van Nostrum RC, Storm G, Hennink WE, Lammers T
Publikováno v:
Biomaterials [Biomaterials] 2013 Jan; Vol. 34 (4), pp. 1255-60. Date of Electronic Publication: 2012 Nov 02.
Autor:
Coimbra M; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Rijcken CJ, Stigter M, Hennink WE, Storm G, Schiffelers RM
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2012 Nov 10; Vol. 163 (3), pp. 361-7. Date of Electronic Publication: 2012 Oct 04.
Autor:
Crielaard BJ; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands., Rijcken CJ, Quan L, van der Wal S, Altintas I, van der Pot M, Kruijtzer JA, Liskamp RM, Schiffelers RM, van Nostrum CF, Hennink WE, Wang D, Lammers T, Storm G
Publikováno v:
Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2012 Jul 16; Vol. 51 (29), pp. 7254-8. Date of Electronic Publication: 2012 Jun 12.